Engineering growth factors for regenerative medicine applications.
暂无分享,去创建一个
Jeffrey A Hubbell | Aaron C Mitchell | Priscilla S Briquez | Jennifer R Cochran | J. Hubbell | J. Cochran | P. Briquez
[1] L. Pannell,et al. Functional and biophysical characterization of recombinant human hepatocyte growth factor isoforms produced in Escherichia coli. , 1997, The Biochemical journal.
[2] J. Cochran,et al. An engineered dimeric fragment of hepatocyte growth factor is a potent c‐MET agonist , 2014, FEBS letters.
[3] L. E. Umoru,et al. Natural Products: A Minefield of Biomaterials , 2012 .
[4] Antonios G Mikos,et al. Gelatin as a delivery vehicle for the controlled release of bioactive molecules. , 2005, Journal of controlled release : official journal of the Controlled Release Society.
[5] Zhifeng Xiao,et al. Collagen scaffolds loaded with collagen-binding NGF-beta accelerate ulcer healing. , 2009, Journal of biomedical materials research. Part A.
[6] Zhifeng Xiao,et al. Linear ordered collagen scaffolds loaded with collagen-binding brain-derived neurotrophic factor improve the recovery of spinal cord injury in rats. , 2009, Tissue engineering. Part A.
[7] Robert Goldman,et al. Growth Factors and Chronic Wound Healing: Past, Present, and Future , 2004, Advances in skin & wound care.
[8] Raymond M. Wang,et al. Delivery of an engineered HGF fragment in an extracellular matrix-derived hydrogel prevents negative LV remodeling post-myocardial infarction. , 2015, Biomaterials.
[9] V. Sasisekharan,et al. Structural specificity of heparin binding in the fibroblast growth factor family of proteins , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[10] F. Veronese. PEGylated protein drugs , 2015 .
[11] Jennie B. Leach,et al. Extracellular Matrix , 2015, Neuromethods.
[12] Stephen F Badylak,et al. Biomaterials for tissue engineering applications. , 2014, Seminars in pediatric surgery.
[13] G. Neufeld,et al. VEGF145, a Secreted Vascular Endothelial Growth Factor Isoform That Binds to Extracellular Matrix* , 1997, The Journal of Biological Chemistry.
[14] M. Jewett,et al. Mimicking the Escherichia coli cytoplasmic environment activates long‐lived and efficient cell‐free protein synthesis , 2004, Biotechnology and bioengineering.
[15] S. Bass,et al. Selecting high-affinity binding proteins by monovalent phage display. , 1991, Biochemistry.
[16] D. Lauffenburger,et al. Rational cytokine design for increased lifetime and enhanced potency using pH-activated “histidine switching” , 2002, Nature Biotechnology.
[17] J. Haugh. Mathematical Model of Human Growth Hormone (hGH)‐Stimulated Cell Proliferation Explains the Efficacy of hGH Variants as Receptor Agonists or Antagonists , 2004, Biotechnology progress.
[18] E. Gherardi,et al. Protein engineered variants of hepatocyte growth factor/scatter factor promote proliferation of primary human hepatocytes and in rodent liver. , 2012, Gastroenterology.
[19] L. Trusolino,et al. MET signalling: principles and functions in development, organ regeneration and cancer , 2010, Nature Reviews Molecular Cell Biology.
[20] C. Cho,et al. Construction of a Novel Extracellular Matrix using a New Genetically Engineered Epidermal Growth Factor Fused to IgG-Fc , 2005, Biotechnology Letters.
[21] Yasuhiko Tabata,et al. Enhanced bone regeneration at a segmental bone defect by controlled release of bone morphogenetic protein-2 from a biodegradable hydrogel. , 2006, Tissue engineering.
[22] J. Wells,et al. Growth hormone binding affinity for its receptor surpasses the requirements for cellular activity. , 1999, Biochemistry.
[23] S. Rizzi,et al. Hyaluronic acid: evaluation as a potential delivery vehicle for vitronectin:growth factor complexes in wound healing applications. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[24] Mikaël M. Martino,et al. Extracellular Matrix-Inspired Growth Factor Delivery Systems for Skin Wound Healing. , 2015, Advances in wound care.
[25] J. Cochran,et al. Engineering hepatocyte growth factor fragments with high stability and activity as Met receptor agonists and antagonists , 2011, Proceedings of the National Academy of Sciences.
[26] M. O’Connor-McCourt,et al. Superagonistic activation of ErbB-1 by EGF-related growth factors with enhanced association and dissociation rate constants. , 2000, The Journal of biological chemistry.
[27] A. Sahni,et al. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. , 2000, Blood.
[28] Jens-Peter Volkmer,et al. Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies , 2013, Science.
[29] Jennifer L. Lahti,et al. Engineered epidermal growth factor mutants with faster binding on‐rates correlate with enhanced receptor activation , 2011, FEBS letters.
[30] D. Mooney,et al. Growth factor delivery-based tissue engineering: general approaches and a review of recent developments , 2011, Journal of The Royal Society Interface.
[31] Daniel Broszczak,et al. Human pilot studies reveal the potential of a vitronectin: growth factor complex as a treatment for chronic wounds , 2011, International wound journal.
[32] Harald C Ott,et al. Organ engineering based on decellularized matrix scaffolds. , 2011, Trends in molecular medicine.
[33] H. Ploegh,et al. Sortase-catalyzed transformations that improve the properties of cytokines , 2011, Proceedings of the National Academy of Sciences.
[34] C. Powers,et al. Fibroblast growth factors, their receptors and signaling. , 2000, Endocrine-related cancer.
[35] W. Murphy,et al. Design of growth factor sequestering biomaterials. , 2014, Chemical communications.
[36] Matthias P Lutolf,et al. Enzymatic formation of modular cell-instructive fibrin analogs for tissue engineering. , 2007, Biomaterials.
[37] Adrian Whitty,et al. Understanding cytokine and growth factor receptor activation mechanisms , 2012, Critical reviews in biochemistry and molecular biology.
[38] M. Lefranc,et al. A simple luciferase assay for signal transduction activity detection of epidermal growth factor displayed on phage. , 1997, Nucleic acids research.
[39] Adrian Ranga,et al. Heparin-binding domain of fibrin(ogen) binds growth factors and promotes tissue repair when incorporated within a synthetic matrix , 2013, Proceedings of the National Academy of Sciences.
[40] J. Hubbell,et al. Engineered insulin-like growth factor-1 for improved smooth muscle regeneration. , 2012, Biomaterials.
[41] E. J. V. van Zoelen,et al. Ligand-induced Lysosomal Epidermal Growth Factor Receptor (EGFR) Degradation Is Preceded by Proteasome-dependent EGFR De-ubiquitination* , 2003, Journal of Biological Chemistry.
[42] C. Mason,et al. A brief definition of regenerative medicine. , 2008, Regenerative medicine.
[43] Philip T. Pienkos,et al. Growth factor engineering by degenerate homoduplex gene family recombination , 2002, Nature Biotechnology.
[44] S. Seif-Naraghi,et al. Injectable extracellular matrix derived hydrogel provides a platform for enhanced retention and delivery of a heparin-binding growth factor. , 2012, Acta Biomaterialia.
[45] Mikaël M. Martino,et al. The 12th-14th type III repeats of fibronectin function as a highly promiscuous growth factor-binding domain. , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[46] Milica Radisic,et al. Scaffolds with covalently immobilized VEGF and Angiopoietin-1 for vascularization of engineered tissues. , 2010, Biomaterials.
[47] Ja Hubbell,et al. Matrix-bound growth factors in tissue repair. , 2006, Swiss medical weekly.
[48] N. Ferrara. Binding to the Extracellular Matrix and Proteolytic Processing: Two Key Mechanisms Regulating Vascular Endothelial Growth Factor Action , 2010, Molecular biology of the cell.
[49] Jeffrey J. Rice,et al. Tenascin C Promiscuously Binds Growth Factors via Its Fifth Fibronectin Type III-Like Domain , 2013, PloS one.
[50] Olena Kravchuk,et al. Vitronectin: growth factor complexes hold potential as a wound therapy approach. , 2008, The Journal of investigative dermatology.
[51] N. Epstein,et al. Complications due to the use of BMP/INFUSE in spine surgery: The evidence continues to mount , 2013, Surgical neurology international.
[52] M. Iruela-Arispe,et al. Extracellular matrix, inflammation, and the angiogenic response. , 2010, Cardiovascular research.
[53] Jihun Lee,et al. Increased Functional Half-life of Fibroblast Growth Factor-1 by Recovering a Vestigial Disulfide Bond , 2013 .
[54] David Silverstein,et al. Growth factor binding to the pericellular matrix and its importance in tissue engineering. , 2007, Advanced drug delivery reviews.
[55] M. Shoichet,et al. Experimental assessment of pro-lymphangiogenic growth factors in the treatment of post-surgical lymphedema following lymphadenectomy , 2010, Breast Cancer Research.
[56] D A Lauffenburger,et al. Intracellular Trafficking of Epidermal Growth Factor Family Ligands Is Directly Influenced by the pH Sensitivity of the Receptor/Ligand Interaction (*) , 1995, The Journal of Biological Chemistry.
[57] Jacqueline Murray,et al. Heparin-II Domain of Fibronectin Is a Vascular Endothelial Growth Factor-Binding Domain: Enhancement of VEGF Biological Activity by a Singular Growth Factor/Matrix Protein Synergism , 2006, Circulation research.
[58] S. Werner,et al. Regulation of wound healing by growth factors and cytokines. , 2003, Physiological reviews.
[59] T. Nakamura,et al. Collagens in the liver extracellular matrix bind hepatocyte growth factor. , 1998, Gastroenterology.
[60] Daa Lipovek,et al. Library Construction For Protein Engineering , 2009 .
[61] Alan Wells,et al. Engineering epidermal growth factor for enhanced mitogenic potency , 1996, Nature Biotechnology.
[62] Shaun M Lippow,et al. Improved mutants from directed evolution are biased to orthologous substitutions. , 2006, Protein engineering, design & selection : PEDS.
[63] Mikaël M. Martino,et al. Biomimetic materials in tissue engineering , 2010 .
[64] Nobuyuki Itoh,et al. Fibroblast growth factors , 2001, Genome Biology.
[65] A. Sahni,et al. FGF‐2 but not FGF‐1 binds fibrin and supports prolonged endothelial cell growth , 2003, Journal of thrombosis and haemostasis : JTH.
[66] Anna T Grazul-Bilska,et al. Wound healing: the role of growth factors. , 2003, Drugs of today.
[67] K D Wittrup,et al. Yeast polypeptide fusion surface display levels predict thermal stability and soluble secretion efficiency. , 1999, Journal of molecular biology.
[68] Jeffrey A. Hubbell,et al. Cell-Demanded Liberation of VEGF121 From Fibrin Implants Induces Local and Controlled Blood Vessel Growth , 2004, Circulation research.
[69] D. M. Brown,et al. An approach to random mutagenesis of DNA using mixtures of triphosphate derivatives of nucleoside analogues. , 1996, Journal of molecular biology.
[70] Junho Park,et al. Overproduction of recombinant human hepatocyte growth factor in Chinese hamster ovary cells. , 2010, Protein expression and purification.
[71] Ralph Müller,et al. Engineering the Growth Factor Microenvironment with Fibronectin Domains to Promote Wound and Bone Tissue Healing , 2011, Science Translational Medicine.
[72] D. Craik. Joseph Rudinger memorial lecture: Discovery and applications of cyclotides , 2013, Journal of peptide science : an official publication of the European Peptide Society.
[73] R. Derynck,et al. Epidermal growth factor and transforming growth factor-alpha: differential intracellular routing and processing of ligand-receptor complexes. , 1991, Cell regulation.
[74] Nobuyuki Itoh,et al. Characterization of Growth Factor-binding Structures in Heparin/Heparan Sulfate Using an Octasaccharide Library* , 2004, Journal of Biological Chemistry.
[75] G. G. Stokes. "J." , 1890, The New Yale Book of Quotations.
[76] Martin Ehrbar,et al. Endothelial cell proliferation and progenitor maturation by fibrin-bound VEGF variants with differential susceptibilities to local cellular activity. , 2005, Journal of controlled release : official journal of the Controlled Release Society.
[77] J. Hubbell,et al. Controlled release of nerve growth factor from a heparin-containing fibrin-based cell ingrowth matrix. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[78] S J Prestrelski,et al. Factors affecting short-term and long-term stabilities of proteins. , 2001, Advanced drug delivery reviews.
[79] Alexander Huber,et al. The effects of processing methods upon mechanical and biologic properties of porcine dermal extracellular matrix scaffolds. , 2010, Biomaterials.
[80] G. Schultz,et al. Interactions between extracellular matrix and growth factors in wound healing , 2009, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.
[81] Mikaël M. Martino,et al. Extracellular matrix-inspired growth factor delivery systems for bone regeneration. , 2015, Advanced drug delivery reviews.
[82] J. Turnbull,et al. Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. , 2011, The Journal of endocrinology.
[83] C. Sarkar,et al. Cell-free Display Systems For Protein Engineering , 2009 .
[84] Stephen F Badylak,et al. Decellularization of tissues and organs. , 2006, Biomaterials.
[85] H. Polk,et al. Enhancement of epidermal regeneration by biosynthetic epidermal growth factor , 1986, The Journal of experimental medicine.
[86] F. V. Cochran,et al. Cell Surface Display Systems For Protein Engineering , 2009 .
[87] M. Götte,et al. Functions of cell surface heparan sulfate proteoglycans. , 1999, Annual review of biochemistry.
[88] Jennifer R Cochran,et al. Discovery of improved EGF agonists using a novel in vitro screening platform. , 2011, Journal of molecular biology.
[89] Hui Zhao,et al. The effect of collagen-binding NGF-beta on the promotion of sciatic nerve regeneration in a rat sciatic nerve crush injury model. , 2009, Biomaterials.
[90] Byung-Soo Kim,et al. Comparison between heparin-conjugated fibrin and collagen sponge as bone morphogenetic protein-2 carriers for bone regeneration , 2012, Experimental & Molecular Medicine.
[91] A. Giaccia,et al. An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis. , 2014, Nature chemical biology.
[92] Mikaël M. Martino,et al. Growth Factors Engineered for Super-Affinity to the Extracellular Matrix Enhance Tissue Healing , 2014, Science.
[93] Y. Tabata,et al. Regeneration of Canine Tracheal Cartilage by Slow Release of Basic Fibroblast Growth Factor from Gelatin Sponge , 2006, ASAIO journal.
[94] Richard T. Lee,et al. Intraarticular injection of heparin-binding insulin-like growth factor 1 sustains delivery of insulin-like growth factor 1 to cartilage through binding to chondroitin sulfate. , 2010, Arthritis and rheumatism.
[95] G. Weiss,et al. Optimizing the affinity and specificity of proteins with molecular display. , 2006, Molecular bioSystems.
[96] R. Dinarvand,et al. Growth factor conjugation: strategies and applications. , 2015, Journal of biomedical materials research. Part A.
[97] Matthias P Lutolf,et al. Biopolymeric delivery matrices for angiogenic growth factors. , 2003, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.
[98] J G Flanagan,et al. Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells , 1992, Molecular and cellular biology.
[99] J M Davidson,et al. Sustained release of epidermal growth factor accelerates wound repair. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[100] Yoshihiro Ito,et al. Covalently immobilized biosignal molecule materials for tissue engineering. , 2007, Soft matter.
[101] E. Schönherr,et al. Extracellular Matrix and Cytokines: A Functional Unit , 2000, Developmental immunology.
[102] Richard O. Hynes,et al. The Extracellular Matrix: Not Just Pretty Fibrils , 2009, Science.
[103] W. Stemmer. DNA shuffling by random fragmentation and reassembly: in vitro recombination for molecular evolution. , 1994, Proceedings of the National Academy of Sciences of the United States of America.